Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex

Everolimus treatment of refractory epilepsy in tuberous sclerosis complex

(2013) Darcy A. Krueger et al.   ANNALS OF NEUROLOGY

A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials

(2013) Michael Wong   Expert Review of Neurotherapeutics

Rapamycin has age-, treatment paradigm-, and model-specific anticonvulsant effects and modulates neuropeptide Y expression in rats

(2012) Tamar Chachua et al.   EPILEPSIA

Adverse events associated with mTOR inhibitors

(2012) Nicolas Pallet et al.   Expert Opinion On Drug Safety

Rapamycin down-regulates KCC2 expression and increases seizure susceptibility to convulsants in immature rats

(2012) X. Huang et al.   NEUROSCIENCE

The mTOR Inhibitor Rapamycin Has Limited Acute Anticonvulsant Effects in Mice

(2012) Adam L. Hartman et al.   PLoS One

Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice

(2011) C. Nicole Sunnen et al.   EPILEPSIA

Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex

(2011) S. Anderl et al.   HUMAN MOLECULAR GENETICS

Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin

(2011) Robert P. Carson et al.   NEUROBIOLOGY OF DISEASE

Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy

(2011) D. M. Escolar et al.   NEUROLOGY

Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex

(2011) J. Goto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of Tuberous Sclerosis Complex

(2010) L.-H. Zeng et al.   HUMAN MOLECULAR GENETICS

Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

(2010) Chelsey Woodrum et al.   Journal of Translational Medicine

Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex

(2010) Ling-Hui Zeng et al.   NEUROBIOLOGY OF DISEASE

The natural history of epilepsy in tuberous sclerosis complex

(2009) Catherine J. Chu-Shore et al.   EPILEPSIA

Preventing and treating posttraumatic seizures: The human experience

(2009) Nancy R. Temkin   EPILEPSIA

Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies

(2009) Michael Wong   EPILEPSIA

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex

(2008) Ling-Hui Zeng et al.   ANNALS OF NEUROLOGY

Clinical Presentation and Diagnosis of Tuberous Sclerosis Complex in Infancy

(2008) Anita N. Datta et al.   JOURNAL OF CHILD NEUROLOGY

Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function

(2008) L. Meikle et al.   JOURNAL OF NEUROSCIENCE